Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Assembly Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Assembly Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Assembly Biosciences's earnings are expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
Assembly Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Assembly Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Assembly Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Assembly Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Assembly Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Assembly Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Assembly Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Derek A. Small is a Co-Founder of Assembly Biosciences, Inc. Mr. Small has been Chief Executive Officer and President at Assembly Biosciences, Inc. since February 17, 2015 and July 11, 2014 respectively. He has been Director of Assembly Biosciences, Inc. since July 11, 2014. Mr. Small served as the Chief Operating Officer and Budget Chief of Assembly Biosciences, Inc. since July 11, 2014. He served as the President at Luson Bioventures, LLC. He served as Head of Business and Corporate Development of Semafore Pharmaceuticals, Inc. From January 2009 to April 2012, Mr. Small also served as a Founding Director, President, and Chief Executive Officer of Coferon, Inc. and served as its Acting Chief Executive Officer. From March 2008 to January 2014, Mr. Small served as a Founding Director, President, and Chief Executive Officer of Naurex, Inc. He was an associate at EMC2 Corporation with responsibilities spanning business development, sales and venture capital channels; and Morgan Stanley previous to that. He is a Director of BioCrossroads. He serves as Director of the Association of Strategic Alliance Professionals (ASAP) Chicago and Midwest chapter and member of ASAP's Global Bio-Pharma Council. He served as a Director of Naurex Inc. He received his BS in Business and Marketing at Franklin College. In addition to his studies in the US, he studied Global Business and International Marketing in England at Harlaxton College.
Derek's compensation has increased whilst company is loss making.
Derek's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Assembly Biosciences management team is less than 2 years, this suggests a new team.
Executive VP & Chief Scientific Officer of Virology Operations
CFO & COO
Vice President of Investor Relations & Corporate Affairs
Senior Vice President of Corporate Development & Strategy
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Assembly Biosciences board of directors is about average.
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company’s microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in two Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in investigational new drug-enabling studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn’s disease, irritable bowel syndrome, non-alcoholic steatohepatitis, and immuno-oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.